Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

945

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Melanoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Placebo for Nivolumab
BIOLOGICAL: Placebo for Ipilimumab

Sponsor

Bristol-Myers Squibb